Lyka Labs Limited (NSE:LYKALABS)
India · Delayed Price · Currency is INR | Market Cap | 2.95B -14.0% |
| Revenue (ttm) | 1.34B -2.7% |
| Net Income | -88.98M |
| EPS | -2.51 |
| Shares Out | 36.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,701 |
| Open | 81.70 |
| Previous Close | 83.21 |
| Day's Range | 81.55 - 81.70 |
| 52-Week Range | 44.10 - 100.94 |
| Beta | 0.59 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Lyka Labs
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations for human and animal healthcare in India and internationally. It offers injectable critical care solutions, anti-infectives, antifungals, anti-ulcer therapies, oncology support, cardiovascular therapies, and women’s healthcare solutions such as gonadotropins, hormonal therapies, and haematinic formulations. The company also develops pharmaceutical and nutritional solutions for livestock, poultry, equine, and companion animals. In additio... [Read more]
Financial Performance
Financial StatementsNews
Lyka Labs shares fall 3% as Q1 net profit falls 20% YoY; Check earnings
Shares of Lyka Labs Ltd. fell by 2.82% to ₹112.90 on Thursday afternoon following the company’s Q1 FY26 earnings announcement, which revealed a 20% year-on-year drop in net profit. Q1 FY26 Highlights ...
Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain
Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitm...